AI assistant
EMV CAPITAL PLC — Share Issue/Capital Change 2015
Nov 16, 2015
7623_sha_2015-11-16_0ef076da-e584-467b-ac13-bbd6c933fabc.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7571F
NetScientific PLC
16 November 2015
NetScientific PLC
("NetScientific" or the "Group")
London, UK - 16 November 2015: NetScientific PLC (AIM: NSCI.L), a transatlantic biomedical healthcare group, announces that it will today apply to admit, in total, 54,167 ordinary shares of 5p each to trading on AIM. Admission is expected on 20 November 2015 and these shares will rank pari passu with the existing ordinary shares in issue.
These shares are being subscribed for by a small number of employees who expressed an interest to the Board in acquiring shares in the Company, but who were unable to as part of the recent fundraising as they were not existing shareholders in NetScientific. None of these employees are directors of the Company. The subscription price is equal to that of the recent fundraising, announced on 1 October 2015, being 120 pence per ordinary share
On Admission, the Company's issued share capital will comprise 51,075,695 Ordinary Shares, none of which will be held in treasury. This figure may be used by shareholders and other investors as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules
-Ends-
Contact Details
| NetScientific plc | Tel: +44 (0)20 3514 1800 | ||
| François Martelet, CEO | |||
| Peter Thoms, CFO | |||
| Investec Bank plc (NOMAD & Broker) Gary Clarence Daniel Adams |
Tel: +44 (0)20 7597 4000 | ||
| Instinctif Partners Melanie Toyne-Sewell Jayne Crook Rosanna Forrest |
Tel: +44 (0)20 7457 2020 [email protected] |
||
About NetScientific
NetScientific is a transatlantic biomedical and healthcare technology group with a differentiated investment strategy focused solely on digital health, diagnostics and therapeutics. The Group's objective is to source, fund and commercialise companies that significantly improve the lives of people with chronic diseases.
For more information, please visit the website at www.netscientific.net.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEPKPDQABDDADD